EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

JETEMA Co. Ltd (216080) fair value: what the stock is really worth

As of Sep 23, 2026: fair value of JETEMA Co. Ltd KRW 1,660, price KRW 7,190, upside -76.9%, quality 25 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · KR

JC Some data Sep 24, 2026

JETEMA Co. Ltd

216080 · KQ

Weakest SetupStrongly overvalued and low quality.

!Fair value 1,660 KRW · Strongly overvalued (−77%)
!Quality 25/100
!Expensive Growth (revenue 5y +30.1 %/yr)
!Loss-making · -6.6% net margin (TTM)
!Moderate debt · negative free cash flow
!Trails peers (1/9)
!Narrow moat 4/100
!Evidence only medium, so the estimate is less certain
!The models disagree: range 496.00 KRW to 2,825 KRW
!Weak on future: 6 out of 100
Watch JETEMA Co. Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card. Watch for free Pro now: $1 first month

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

20,100 KRW 4,050 KRW Fair Value 1,660 KRW May 2021 Sep 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 24, 2026.

How to read this chart

60‑month range 4,050 KRW – 20,100 KRW · fair‑value band 496.00 KRW – 2,825 KRW · the 7,190 KRW price screens above the 1,660 KRW fair value. Dashed = 300-day average. As of Sep 24, 2026.

Follow JETEMA Co. in your weekly email

Every Wednesday you see whether JETEMA Co. is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names.

Show more

JETEMA, Co., Ltd., a bio venture company, engages in the research and development of medicines and medical devices. It offers clostridium botulinum toxins, fillers, lifting threads for medical treatment, elastin and collagen stimulate solution under Ecolla, and healthy skin care under vitten brand names. The company also provides skin care hyaluronic acid masks. JETEMA, Co., Ltd. was founded in 2009 and is headquartered in Wonju-si, South Korea.

Stock analysis

JETEMA Co. Ltd (216080) currently trades at 7,190 KRW, while our model-based Fair Value estimate is 1,660 KRW, implying the stock looks roughly 333.1% overvalued today.

Show more

Valuation

Bull case: the Asset-Based group reads highest at a median of 1,179 KRW per share, and 0 of the 4 models we run sit above the 7,190 KRW price.

Bear case: the Multiples group reads lowest at 529.82 KRW, and 4 of the 4 models stay below the price. Evidence for this calculation is medium.

Scenario range: 496.00 KRW (bear) to 2,825 KRW (bull), the price of 7,190 KRW sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 25/100 (below-average quality), in the Healthcare sector.

Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.

JETEMA Co. Ltd reported revenue of 76.9B KRW in FY2025 versus 33.2B KRW in FY2021, a compound +23.3%/yr. Reported net income was −6.6B KRW in FY2025.

Key figures

Market cap 258B KRW · P/S ratio 2.03 · Net margin −8.6% · Return on equity −8.2% · Return on assets (EBIT) 0.5% · Operating margin −4.2% · Revenue (TTM) 77.1B KRW · Revenue growth (YoY) +1.1%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).

What moves the price

The share trades about 34% below its 52-week high and 78% above its 52-week low, currently above its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −12% fair-value upside, at −77%, 216080 screens richer than that median.

Fair Value models

Bear 496.00 KRW Fair Value 1,660 KRW Bull 2,825 KRW
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
EV/EBITDA 2,278 KRW 3,442 KRW 4,607 KRW 66
EV/EBIT 93.60 KRW 529.82 KRW 966.04 KRW 58
NCAV (Graham) 879.60 KRW 1,179 KRW 1,759 KRW 54
All 4 models by family
Multiples
EV/EBIT 93.60 KRW 529.82 KRW 966.04 KRW 58
EV/EBITDA 2,278 KRW 3,442 KRW 4,607 KRW 66
EV/Revenue n/a 119.26 KRW 519.56 KRW 50
Asset-Based
NCAV (Graham) 879.60 KRW 1,179 KRW 1,759 KRW 54

Open the full fair value analysis →

Notify me when 216080 reaches fair value

Put 216080 on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.

Set up alert →

Quality Score breakdown

Overall quality 25/100

Of which business quality 27 · Market factors (momentum, volatility) 45

Profitability 12
Margins and returns on capital today
Quality Growth 50
Are margins and returns improving?
Cashflow 19
Earnings quality: real cash, not paper profit
Fin. Strength 12
Balance sheet, leverage, solvency risk
Investment 53
Disciplined investing over empire-building
Low Volatility 45
Calm price path (market factor)
Momentum 41
Price trend over the last 3–12 months (market factor)
52W Momentum 50
Distance to the 52-week high (market factor)
Net Issuance 39
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 38/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+12.2%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+18.7%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+30.1%
Start year 2020 (pandemic)
Revenue growth 8 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+32.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−27.0% (2020) → 5.0% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

216080 screens 333% overvalued. Compare with Intuitive Surgical, Inc →

Compare JETEMA Co. Ltd with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Instruments & Supplies · 203 stocks

Beats the industry median on 1/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 25 · Bottom 25%
Fair Value upside −77% · Bottom 25%
Profitability
Return on assets 1% · Below median
Net margin (TTM) −7% · Bottom 25%
Operating margin (TTM) −4% · Bottom 25%
Growth and dividend
Revenue growth 1% · Below median
Balance sheet
Debt / equity 0.77× · Highest 25%

Valuation Multiplesvs Medical Instruments & Supplies median · lower = cheaper

EV/EBITDA 3.9× · Cheapest 25%

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)0 · sector 17
FUTURE (revenue growth)6 · sector 31
PAST (return on equity)0 · sector 25
HEALTH (low debt)62 · sector 96
DIVIDEND (yield)0 · sector 33

VALUE 0: the price sits above our fair-value range.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value
Intuitive Surgical, Inc ISRG $402.09 $353.38 −12%
EssilorLuxottica Société anonyme EL €144.70 €159.17 +10%
Medline Inc MDLN $34.30 $30.15 −12%
Becton, Dickinson and Company BDX $182.52 $103.53 −43%
Alcon Inc ALC $65.39 $39.78 −39%
ResMed Inc RMD A$31.70 A$34.87 +10%
West Pharmaceutical Services, Inc WST $375.87 $137.28 −63%
Sartorius Stedim Biotech S.A DIM €215.80 €54.82 −75%
Straumann Holding STMN CHF 96.38 CHF 45.50 −53%
Solventum Corporation SOLV $88.75 $130.51 +47%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorFama-French ModelIntrinsic Value
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

JETEMA Co. Ltd · Fair Value
1,660 KRW −333%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "JETEMA Co. Ltd Fair Value". https://www.fairvalue-calculator.com/stock/216080

Frequently asked questions

Is JETEMA Co. Ltd (216080) overvalued or undervalued?
As of Sep 24, 2026, our model estimates a fair value of 1,660 KRW versus a price of 7,190 KRW, about −77% upside (overvalued).
What is the fair value of 216080?
Our model-based fair value for JETEMA Co. Ltd is 1,660 KRW (as of Sep 24, 2026), built from audited fundamentals. The current price: 7,190 KRW.
What is the quality score of 216080?
JETEMA Co. Ltd has a Quality Score of 25/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for JETEMA Co. Ltd (216080)?
Our model-based price target is the fair value of 1,660 KRW (as of Sep 24, 2026) from 4 valuation models. Cautious scenario 496.00 KRW, optimistic scenario 2,825 KRW. It is a calculation from audited fundamentals, not an analyst target.
What is the JETEMA Co. Ltd stock forecast for 2026?
Our models put fair value at 1,660 KRW, about −77% upside versus a price of 7,190 KRW (overvalued). Cautious scenario 496.00 KRW, optimistic scenario 2,825 KRW. The calculation is refreshed regularly with new filings.
What is the revenue of JETEMA Co. Ltd (216080)?
JETEMA Co. Ltd reported trailing-twelve-month revenue of about 77.1B KRW (latest available figure, as of Sep 24, 2026).
What is the intrinsic value of JETEMA Co. Ltd (216080)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For JETEMA Co. Ltd it is 1,660 KRW per share (as of Sep 24, 2026), against a price of 7,190 KRW. It is the blended result of 4 valuation models (cash flow, earnings, asset, dividend).
Is JETEMA Co. Ltd stock overvalued or undervalued in 2026?
As of Sep 24, 2026, 216080 trades above its calculated fair value: price 7,190 KRW, fair value 1,660 KRW, a gap of about −77% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 216080?
No. The price is what the market pays today (7,190 KRW); the fair value is what the company's own numbers justify (1,660 KRW). For JETEMA Co. Ltd the two are 5,530 KRW per share apart. That gap is exactly why we show both numbers side by side.
How much is JETEMA Co. Ltd worth?
The market values JETEMA Co. Ltd at about 258B KRW (market capitalisation, as of Sep 24, 2026). Per share that is 7,190 KRW; our models calculate a fair value of 1,660 KRW per share.
What do the bullish and bearish scenarios say about 216080?
Our models span a range for JETEMA Co. Ltd: cautious scenario 496.00 KRW, base 1,660 KRW, optimistic 2,825 KRW per share (as of Sep 24, 2026, price 7,190 KRW). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of JETEMA Co. Ltd (216080)?
Balance-sheet figures for JETEMA Co. Ltd (as of Sep 24, 2026): return on equity −8.2%, debt of 0.77 per unit of equity. They feed the Quality Score of 25/100, which measures business quality independently of the share price.
How far is 216080 from its 52-week high?
JETEMA Co. Ltd trades at 7,190 KRW, about 34% below its 52-week high of 10,890 KRW and 78% above the low of 4,050 KRW (as of Sep 23, 2026). Distance from the high says nothing about value: that is what the fair value of 1,660 KRW is for.
Which stocks are comparable to JETEMA Co. Ltd?
From the same area (Healthcare) we also value Intuitive Surgical, Inc, EssilorLuxottica Société anonyme, Medline Inc, Becton, Dickinson and Company, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is JETEMA Co. Ltd stock attractive at the current price?
The data as of Sep 24, 2026: price 7,190 KRW, calculated fair value 1,660 KRW (−77%), Quality Score 25/100, from 4 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 216080 calculated?
We run JETEMA Co. Ltd through 4 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 1,660 KRW, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.0 % above its aggregate fair value. JETEMA Co. Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of JETEMA Co. Ltd (216080)?
The closing price on Sep 23, 2026 was 7,190 KRW. Our model-based fair value is 1,660 KRW, about −77% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with JETEMA Co. Ltd right now?
The price sits above even our optimistic bull case (2,825 KRW). The favourable scenario is already priced in. Weak quality (25/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (496.00 KRW to 2,825 KRW). The outcome hinges heavily on assumptions, so read the point estimate with caution.

Key figures of JETEMA Co. Ltd

How large is the market capitalisation of JETEMA Co. Ltd (216080)?
The market capitalisation of JETEMA Co. Ltd is 258B KRW. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of JETEMA Co. Ltd (216080)?
The price-to-sales ratio of JETEMA Co. Ltd is 2.03 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of JETEMA Co. Ltd (216080)?
The net margin of JETEMA Co. Ltd is −8.6% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of JETEMA Co. Ltd (216080)?
The return on equity (ROE) of JETEMA Co. Ltd is −8.2% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of JETEMA Co. Ltd (216080)?
On an EBIT basis the return on assets of JETEMA Co. Ltd is 0.5% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of JETEMA Co. Ltd (216080)?
The operating margin of JETEMA Co. Ltd is −4.2% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at JETEMA Co. Ltd (216080)?
Revenue at JETEMA Co. Ltd is growing +1.1% versus a year earlier (3y avg +18.7%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at JETEMA Co. Ltd (216080)?
Earnings per share at JETEMA Co. Ltd are growing −39.0% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does JETEMA Co. Ltd (216080) generate?
The free cash flow of JETEMA Co. Ltd is −4.8B KRW (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does JETEMA Co. Ltd (216080) carry?
The net debt of JETEMA Co. Ltd is 112B KRW (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch JETEMA Co. Ltd in the live analysis

One click puts JETEMA Co. Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.